and outcome of lung SpCC.The efficacy of molecular targeted therapy for this tumor is still unclear.[1]Here,we report an adult male with metastatic SpCC harboring a Tropomyosin 3-ROS proto-oncogene 1(TPM3-ROS1)fusion who showed a long-term response to targeted therapy by crizotinib,a ...